Influenza virus and Epstein-Barr virus peptides
| CEF product | Peptide sequence | Catalog no. | Quantity | GBP |
| CEF1, Influenza Matrix Protein M1 (58 – 66) | GILGFVFTL | AB-CEF001 | 1 mg | £105 |
| CEF2, Influenza Virus PA (46 – 54) | FMYSDFHFI | AB-CEF002 | 1 mg | £105 |
| CEF3, Influenza Virus M1 (13 – 21) | SIIPSGPLK | AB-CEF003 | 1 mg | £105 |
| CEF4, Influenza Virus NP (342 – 351) | RVLSFIKGTK | AB-CEF004 | 1 mg | £105 |
| CEF5, Influenza Virus NP (91 – 99) | KTGGPIYKR | AB-CEF005 | 1 mg | £105 |
| CEF6, Influenza Virus NP | LPFDKTTVM | AB-CEF006 | 1 mg | £105 |
| CEF7, Influenza Virus NP (380 – 388) | ELRSRYWAI | AB-CEF007 | 1 mg | £105 |
| CEF8, Influenza Virus NP (383 – 391) | SRYWAIRTR | AB-CEF008 | 1 mg | £105 |
| CEF9, Influenza Virus M1 128 – 135 | ASCMGLIY | AB-CEF009 | 1 mg | £105 |
| CEF10, Epstein – Barr Virus LMP2 (426 – 434) | CLGGLLTMV | AB-CEF010 | 1 mg | £105 |
| CEF11, Epstein – Barr Virus BMLF1 (280 – 288) | GLCTLVAML | AB-CEF011 | 1 mg | £105 |
| CEF12, Epstein – Barr Virus latent NA3B (399 – 408), AVF | AVFDRKSDAK | AB-CEF012 | 1 mg | £105 |
| CEF14, Epstein – Barr Virus RTA Protein (28 – 37) | DYCNVLNKEF | AB-CEF014 | 1 mg | £105 |
| CEF15, Epstein – Barr Virus Lytic Cycle Protein BZLF – 1(190 – 197) | RAKFKQLL | AB-CEF015 | 1 mg | £105 |
| CEF16, Epstein – Barr Virus latent NA – 3A (337 – 347) | FLRGRAYGL | AB-CEF016 | 1 mg | £105 |
| CEF17, Epstein – Barr Virus latent NA – 3A (158 – 166) | QAKWRLQTL | AB-CEF017 | 1 mg | £105 |
| CEF18, Epstein – Barr Virus latent NA – 3C (258 – 266) | RRIYDLIEL | AB-CEF018 | 1 mg | £105 |
| CEF19, Epstein – Barr Virus latent NA – 3A (458 – 466) | YPLHEQHGM | AB-CEF019 | 1 mg | £105 |
| CEF20, Cytomegalovirus, CMV pp65 (495 – 503) | NLVPMVATV | AB-CEF020 | 1 mg | £105 |
| CEF21, Cytomegalovirus, CMV pp65 (417 – 426) | TPRVTGGGAM | AB-CEF021 | 1 mg | £105 |
| CEF22, Cytomegalovirus, CMV pp65 (378 – 389) | SDEEEAIVAYTL | AB-CEF022 | 1 mg | £105 |
| CEF23, Cytomegalovirus, CMV pp65 (123 – 131) | IPSINVHHY | AB-CEF023 | 1 mg | £105 |
| CEF24, Influenza Virus PB1 Peptide (591 – 599) | VSDGGPNLY | AB-CEF024 | 1 mg | £105 |
| CEF25, Influenza Virus NP (44 – 52) | CTELKLSDY | AB-CEF025 | 1 mg | £105 |
| CEF26, Influenza Virus NP (265 – 274) | ILRGSVAHK | AB-CEF026 | 1 mg | £105 |
| CEF27, Epstein – Barr Virus BRLF – 1 lytic (148 – 156) | RVRAYTYSK | AB-CEF027 | 1 mg | £105 |
| CEF28, Epstein – Barr Virus latent NA – 3A (603 – 611) | RLRAEAQVK | AB-CEF028 | 1 mg | £105 |
| CEF29, Epstein – Barr Virus latent NA – 3B (416 – 424) | IVTDFSVIK | AB-CEF029 | 1 mg | £105 |
| CEF30, Epstein – Barr Virus BRLF1 (134 – 142) | ATIGTAMYK | AB-CEF030 | 1 mg | £105 |
| CEF31, Epstein – Barr Virus latent NA – 3A (379 – 387) | RPPIFIRRL | AB-CEF031 | 1 mg | £105 |
| CEF32, Epstein – Barr Virus latent NA – 3C (281 – 290) | EENLLDFVRF | AB-CEF032 | 1 mg | £105 |
| CEF33, Cytomegalovirus, HCMV pp65 | EFFWDANDIY | AB-CEF033 | 1 mg | £105 |
Related articles
Peptide Oligonucleotide Conjugates for Life Science Research
The conjugation of peptides to oligos is highly advantageous. It broadens their applications by enhancing them with additional unique properties. Read more.
Histone peptides and microarrays
AltaBioscience stock a selection of individual histone peptides and 5 different histone peptide sets. The peptide sequences are derived from human histones H2A, H2B, H3 and H4 and include a range of modified amino acids.
Histone Peptides
AltaBioscience has provided custom synthesis of histone peptides from human H2a, H2b, H3 and H4 regions for many years, having collaborated with the original scientist who developed the idea for histone assays.